Janice L Gabrilove, MD
- PROFESSOR | Medicine, Hematology and Medical Oncology
- PROFESSOR | Oncological Sciences
Specialties:
Cancer (Oncology), Hematology-OncologyResearch Topics:
Bioinformatics, Biophysics, Computational Biology, Computer Simulation, Drug Design and Discovery, Integrins, Mathematical and Computational Biology, Membrane Proteins/Channels, Protein Complexes, Protein Structure/Function, Signal Transduction, Theoretical Biology, Theoretical BiophysicsJanice Gabrilove, MD, FACP, is The James F. Holland Professor of Medicine at the Icahn School of Medicine at Mount Sinai. She is the Director of the Clinical Research Education Program (Certificate, Master of Science, and PhD in Clinical Research) at the Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, and Co-Director of the Patient Oriented Research Training And Leadership (PORTAL) Program, a joint MD/Master of Science in Clinical Research Program. Dr. Gabrilove is also the Associate Director of Education and Training at The Tisch Cancer Institute.
Dr. Gabrilove is a world-renowned expert on the biology of hematopoietic growth factors in normal and malignant hematopoiesis and the role of these cytokines in ameliorating disease and treatment-related myelosuppression. She is a co-inventor on the patent describing the initial isolation and characterization of human granulocyte colony stimulating factor (G-CSF), which is used in the treatment of chemotherapy-induced myelosuppression and severe chronic neutropenia. Her initial studies demonstrated the ability of G-CSF to mobilize progenitor cells into the peripheral blood (PBPC). This observation revolutionized the way we perform stem cell transplantation today, utilizing G-CSF mobilized PBPC.
Dr. Gabrilove has been intimately involved in the development of novel therapeutics for fostering leukemic cell maturation, and received patents for two Food and Drug Administration (FDA) approved drugs for the treatment of Acute Promyelocytic Leukemia. She has served on the FDA Advisory Committee for the Approval of Biologics.
An elected member of the American Society for Clinical Investigation (ASCI), Dr. Gabrilove has received numerous awards in recognition of excellence in education, teaching and clinical care. Actively engaged in career development, she has mentored more than 38 residents, Hematology/Oncology fellows, and junior faculty.
Certifications
Medical Oncology
American Board of Internal Medicine
Clinical Focus
- Acute Lymphoid Leukemia
- Acute Myeloid Leukemia
- Adult Non-Hodgkin's Lymphoma
- Bone Marrow Biopsy
- Chemotherapy
- Hematologic Malignancies
- Hodgkin's Disease
- Hodgkin's Lymphoma
- Leukemia
- Lymphoma
- Myelodysplastic Syndromes
- Waldenström's Macroglobulinemia
Education
MD, Mount Sinai School of Medicine
Residency, Internal Medicine, Columbia-Presbyterian Medical Ctr.
Fellowship, Hematology-Oncology, Memorial Sloan-Kettering
-
2009
Best Doctors
Role of Hematopoietic Factors in Normal Hematopoietic Cell Reconstitution
Dr. Gabrilove is a pioneer in the development of our understanding of the biology of hematopoietic growth factors and their clinical utility in promoting hematopoietic reconstitution. She is a co-inventor on the patent describing the initial isolation and characterization of human granulocyte colony stimulating factor (G-CSF), which is used in the treatment of chemotherapy induced myelosuppression and severe chronic neutropenia. Her initial studies also demonstrated the ability of G-CSF to mobilize progenitor cells into the peripheral blood (PBPC). This observation has revolutionized the way in which we perform marrow transplantation today, which is conducted almost exclusively utilizing G-CSF mobilized PBPC. This laboratory is currently investigating:
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Gabrilove during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.
- Association for Clinical and Translational Science
Royalty Payments:
- Amgen Inc.; Cephalon, Inc.
Scientific Advisory Board:
- Leukemia & Lymphoma Society
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.